Information checked: November 9, 2026, at 9:05 p.m. UTC (UTC+00:00).
The U.S. Food and Drug Administration is requiring a warning about a potential increased risk of a rare but serious eye condition, non-arteritic anterior ischemic optic neuropathy (NAION), in the prescribing information for all GLP-1 receptor agonist medicines. The November 9, 2026, action covers drugs including Ozempic and Zepbound. NAION can cause sudden, painless vision loss, sometimes permanently.
The condition remains rare, and the evidence does not establish exactly how these medicines might contribute to it. Anyone who notices sudden vision loss or another new visual disturbance should contact a health care professional immediately. The FDA advises people who have experienced NAION to discuss whether to continue their medication with their clinician.
Destaques
The FDA safety communication says manufacturers must add information about the potential increased risk of NAION to the Warnings and Precautions section of labeling for all GLP-1 receptor agonists. The requirement is a labeling change; the agency's announcement does not say the medicines are being withdrawn.
Ozempic contains semaglutide, a GLP-1 receptor agonist used for type 2 diabetes. Zepbound contains tirzepatide, which acts on both GLP-1 and GIP receptors. The FDA includes tirzepatide products in its action. Other medicines covered include Wegovy, Rybelsus and Mounjaro. Different products have different approved uses, so their benefits and alternatives depend on the individual patient's condition.
NAION is damage to the front portion of the optic nerve associated with reduced blood flow. The optic nerve carries visual information from the eye to the brain. When its fibers are injured, the result can be a missing area in the visual field, reduced sharpness or other loss of vision. The underlying reason the blood flow decreases is not completely understood.
Symptoms generally appear suddenly and without pain, often in one eye. A person may notice the change on waking. The FDA lists blurred or missing areas of vision, blind spots or tunnel vision, distorted colors, and hazy or blurry spots among the possible signs. Vision loss can be permanent. A prior episode in one eye raises the risk of an episode in the other eye.
NAION is not the same condition as diabetic retinopathy, which affects blood vessels in the retina. Both can affect vision, and a new symptom cannot be reliably diagnosed at home. An eye specialist can examine the optic nerve and assess other possible causes of vision loss.
The FDA reviewed clinical trials, observational studies, adverse event reports and animal data. Across 126 randomized controlled trials involving more than 134,000 participants, it identified 15 probable NAION events: 10 among people assigned a GLP-1 medicine and five among those assigned a placebo. The agency found none among participants assigned another type of glucose-lowering medicine.
Accounting for the time participants were observed, the rates were 6.4 events per 100,000 person-years in the GLP-1 group and 3.8 per 100,000 person-years in the combined comparison group. A person-year is one person followed for one year; the figures are rates across the studies, not a precise prediction of any one patient's risk. Because there were so few events, they also do not establish a separate risk estimate for Ozempic or Zepbound.
Other evidence is not uniform. In the FDA's own observational analysis of adults with type 2 diabetes, the agency found no statistically significant increase compared with SGLT-2 inhibitors, but did find an increase compared with DPP-4 inhibitors. Such studies can be affected by differences between patient groups. The FDA also noted that risk factors for NAION often overlap with conditions common among people prescribed these medicines.
The agency found no mechanism in its review of animal data that explained how GLP-1 medicines could increase NAION risk. Its conclusion is a potential increased risk, rather than proof that a particular medicine caused any individual case.
NAION can occur in people who have never taken a GLP-1 medicine. According to the FDA, risk factors may include diabetes, high blood pressure, sleep apnea, anemia, kidney disease and smoking. A previous NAION episode is also relevant. Having one of these factors does not mean a person will develop the condition, and the FDA's announcement does not provide a personalized risk calculator.
The European Medicines Agency previously concluded that NAION is a very rare side effect of semaglutide medicines. That 2025 assessment concerned semaglutide; the FDA's 2026 action covers the broader GLP-1 drug class, including tirzepatide.
Contact a health care professional right away for sudden painless vision loss, a new blind spot or another sudden visual disturbance. If you cannot promptly reach a clinician, seek urgent in-person care. Do not wait for a routine eye appointment to report a sudden change. The FDA tells health professionals to promptly refer patients with suspected NAION to an ophthalmologist.
If you have had NAION, discuss the treatment decision with your prescribing clinician. The FDA advises clinicians to consider discontinuing a GLP-1 medicine when a patient develops NAION unless treatment benefits clearly outweigh the risk. For someone without symptoms, the warning is a reason to understand the signs and discuss individual risks and benefits with their clinician; it does not mean every patient should stop treatment.
As manufacturers update prescribing information and researchers continue to study these rare events, estimates may change. The FDA's current class-wide warning is based on the evidence available in its November 2026 review.
The FDA has identified a potential increased risk of NAION, which can cause permanent vision loss. The condition is rare, and the evidence does not establish that a drug caused a particular person's vision loss.
NAION typically causes sudden vision loss without pain, often in one eye. A painless change still needs immediate medical attention.
The FDA does not instruct all patients to stop because of the warning. Discuss your individual risks and treatment benefits with your clinician; if you experience sudden visual symptoms, contact a health care professional immediately.
Nineteen David Jones stores are expected to close by year-end. Here’s what shoppers should know about gift cards, returns and paid online orders.
Severe storm warnings and forecast risks vary by region in Australia. Get Bureau of Meteorology updates, shelter and flood safety advice, and outage guidance.
David Jones will close 19 stores across Australia and New Zealand by year-end. See the confirmed locations, expected timeline and what remains undecided.
The Bureau of Meteorology forecasts storms across several regions on November 12, with severe weather possible in southeast Queensland and parts of New South Wales.
Fallout 5 is in preproduction on Creation Engine 3, but Bethesda has announced no release date, platforms, or PC requirements. Here’s what UK gamers should—and shouldn’t—buy now.
Fallout 5 remains in preproduction, with no release date or platforms confirmed. Here is Bethesda’s latest status update and what it means for UK players.
Bethesda says Fallout 5 is in preproduction on Creation Engine 3, with The Elder Scrolls VI its main focus. Here is what is confirmed—and what remains unknown.
An ICE charter carrying Iranian detainees reportedly returned to Mesa after Pakistan refused the group. Here’s what’s known, what remains unclear and how it differs from an earlier canceled flight.
Kyle McCord is in line for his first Dolphins start after Malik Willis went on IR. See his profile, NFL fit, Colts kickoff time and what it could mean for Miami’s 2027 draft.
Miami placed Malik Willis on injured reserve, opening the door for Kyle McCord to start against Indianapolis. Here’s what the move means for the Dolphins’ QB depth chart.
